Transparency and Disclosure

Cycle appreciates that the pharmaceutical industry must recognise and support transparency as an important means of building and maintaining confidence and trust with the general public. Transparency demonstrates the integrity of our interactions and relationships with healthcare professionals, and healthcare and patient organisations.

Where appropriate, Cycle is proud to support patients, healthcare organisations, charities and universities through a variety of grants, donations and collaborative projects. As part of this support, Cycle is committed to increasing its transparency: committed to being open about how we operate as a business and our relationships.

Working with Healthcare Professionals

Cycle values enormously the advice and counsel it receives from healthcare professionals and healthcare organisations to support better patient outcomes. These insights enable the development of new and innovative medicines and diagnostics as well as educational services to ensure patients continue to gain access to optimal care. As with any professional group providing expert advice, it is fair and appropriate to provide remuneration for their valuable time and expertise. Disclosing the value of these interactions is an important part of Cycle's commitment to transparency.

Patient Organisation Support

Cycle acknowledges that patient organisations play an important role in improving healthcare for patients. We are proud to support and collaborate with these groups but respect their independence, which should never be compromised. We aim to be transparent about all our interactions with patient organisations.

Each year we produce an full list of grants and donations. In 2021, which was a second exceptional year due to COVID restrictions, no communal face to face patient or HCP gatherings were appropriate, and so no grants were made.

Global Grant Disclosures – Cycle Pharmaceuticals Ltd
(from January to December 2021)

Activity	Grant Date	End Date	Organization, Address	Total Spend (in USD)
NIL				